- Humanized Models
- PBMC/NK Models, NOG Mouse Model (Coming Soon)
- Induction Models of Cancer and Fibrosis (lung, liver)
- DEN, CCl4, Choline Deficient Diet
Primary (PDX) Glioblastoma Models
Get a unique look into the various glioblastoma disease types with more than 40 first-presentation and recurrent models—now available for in vivo and in vitro analysis as both subcutaneous and orthotopic models:
- MOA-Based Filters: Find the right models through selections driven by your drug’s specific mechanism of action (MOA) and subsequent interrogation.
- Diverse Tissue Types: Fixed tissue can also be made available for analysis of novel markers.
- Assess Tumor Progression: Through validated orthotopic primary tumor models, you can assess drug effects on tumor progression as single agents and in combination with standard therapies, including chemotherapies and radiation. These models are also available for in vitro analysis to assist in identifying mechanistic targets.
- Vetted for High Survival Rate: Well-established protocols for efficient surgical implantation ensure an extremely high post-surgery survival rate.
- Data-Rich Models: Get highly-characterized models that have standard of care (SOC) data and patient information on a subset of lines.
We define rare disease in many ways—rare in incidence, mutationally rare within a larger indication, etc.—and have an ongoing effort to validate new models that represent an unmet medical need.
Multiple Myeloma Transgenic Mouse Model
Improve multiple myeloma efficacy studies with more than 60 agents from Vk-Myc, a genetically engineered, clinically predictive mouse model from Dr. Leif Bersagel’s lab at the Mayo Clinic. Monitor treatment effects on the clinically-relevant M-protein levels to assess efficacy. Studies have linked the model’s high correlation with clinical outcomes in patients.